Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

2.365 -0.065 (-2.67%)
Streaming Delayed Price Updated: 10:12 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
SPERO THERAPEUTICS INC (NASDAQ:SPRO) Reports Mixed Q2 2025 Results with Revenue Beat but Stock Decline
SPERO Therapeutics (SPRO) reported Q2 2025 results with $14.19M revenue, beating estimates, but shares fell 6.8%. Phase 3 trial for tebipenem HBr halted early for efficacy. 
Via Chartmill
Earnings Outlook For Spero Therapeutics
 
Via Benzinga
An Overview of Spero Therapeutics's Earnings
 
Via Benzinga
A Glimpse of Spero Therapeutics's Earnings Potential
 
Via Benzinga
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts
 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Unusual volume stocks in Friday's session
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
What 4 Analyst Ratings Have To Say About Spero Therapeutics
 
Via Benzinga
Spero Therapeutics's Earnings Outlook
 
Via Benzinga
The trading volume of these stocks is deviating from the norm in today's session.
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
These stocks are making the most noise in today's session.
Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
Small-Cap Movers Under $1: HIT, SPRO, SGN, PRSO, SGBX Drive Momentum Across AI, Biotech, Crypto, Software, Etc.
Via AB Newswire
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast
Via Benzinga
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S. 
Via Benzinga
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings
 
Via Benzinga
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled
The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For March 27, 2025
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Earnings Scheduled For November 14, 2024
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
SPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.